Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01568723 · ClinicalTrials.gov registry record
Betrnet Stem Cells and the Origins of Barrett's Esophagus Project 3 RF Ablation
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 125
- Enrollment target
NCT01568723: Completed study, sponsored by Mayo Clinic.
NCT01568723 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 125 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01568723 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 125 participants
- Enrollment target
Study Summary
The purpose of this study is to determine biomarkers which can predict response to ablation therapy in patients with Barretts esophagus.
Primary Outcome
evaulation will be made at 3 month intervals for one year post ablation
Interventions
- GENETIC response to therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2012-01 |
| Est. Completion | 2018-08-16 |
What the finished NCT01568723 record still lists
NCT01568723 is an observational study that tracks outcomes without assigning an intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which response to therapy is the first listed.
NCT01568723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01568723 about?
NCT01568723 is a clinical study titled "Betrnet Stem Cells and the Origins of Barrett's Esophagus Project 3 RF Ablation". The purpose of this study is to determine biomarkers which can predict response to ablation therapy in patients with Barretts esophagus.
What is the current status of trial NCT01568723?
This trial is currently completed. The enrollment target is 125 participants. The study started on 2012-01. Estimated completion is 2018-08-16.
What interventions are being tested in trial NCT01568723?
The interventions under investigation include: response to therapy (GENETIC).
Who is sponsoring clinical trial NCT01568723?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia